Composition and Tenure

Prior to the end of each calendar year, the President shall appoint a Nominating Committee composed of seven members in good standing who are not, at the time of their appointment, members of the Board of Directors. Six of the members shall not have served on the Nominating Committee during the previous three years. One member shall have been a member of the immediately preceding Nominating Committee. One member shall have served previously on the Board of Directors. The President shall designate one member of the committee to be Chairperson. The committee shall take office on the January 1st succeeding appointment.

Procedures

A call for nominations shall be sent to the membership at least eight weeks prior to the distribution of ballots. The ballot shall be composed by the Nominating Committee and shall consist of at least one candidate for President-elect and at least six candidates for director. Members of the Nominating Committee shall not be eligible for nomination. The period between ballot distribution and the Annual Meeting shall be no less than 12 weeks. The ballot shall also make provision for voting for persons whose names do not appear on the ballot.

Distinguished leaders in the field of human genetics should be considered as candidates for the presidential office, but it is emphasized that the President should be willing and able to discharge specific administrative and leadership responsibilities. These duties should be defined and explained to the candidate(s) by the chairperson of the Nominating Committee as part of the nominating process. Only those individuals who express a willingness to assume these responsibilities should be put forward as presidential candidates. The Board of Directors recognizes the diversity of opinion regarding the option of placing more than one President-elect candidate on the ballot. Candidates for director must be willing to attend the spring and fall Board meetings and possibly to assume ad hoc responsibilities for various projects. Candidates proposed by the Nominating Committee should be as broadly representative of the membership's interests as possible.

2017 Committee Members


Kay E. Davies, PhD Chair (2017)
Department of Phyiology, Anatomy, and Genetics
University of Oxford
Parks Rd
Oxford, United Kingdom, 0X1 3PT
T: 44 1865-285880
kay.davies@dpag.ox.ac.uk
Barbara A. Bernhardt, MS (2017)
Division of Translational Medicine and Human Genetics
University of Pennsylvania
3400 Spruce Street, 5 Silverstein
Philadelphia, PA, 19104
T: (215) 662-474
barbara.bernhardt@uphs.upenn.edu
Kym M. Boycott, MD (2017)
Department of Genetics
Children's Hospital of Eastern Ontario
401 Smyth Rd
Ottawa, ON, Canada, K1H 8L1
T: (613) 737-7600
kboycott@cheo.on.ca
William B. Dobyns, MD (2018)
Ctr Integrative Brain Research
Seattle Children's Res Inst
1900 Ninth Ave
Seattle, WA, 98101
T: (206) 884-1307
wbd@uw.edu
Michael P. Epstein, PhD (2018)
Department of Human Genetics
Emory University
615 Michael St, Ste 301
Atlanta, GA, 30322
T: (404) 712-8289
mepstein@genetics.emory.edu
Ian D. Krantz, MD (2017)
Department of Pediatrics/ Human Genetics
Children's Hospital of Philadelphia
3615 Civic Ctr Blvd
Philadelphia, PA, 19104
T: (215) 590-2931
ian2@mail.med.upenn.edu
Mark McCarthy, MD (2018)
Oxford Centre for Diabetes, Endocrinology & Metabolism
University of Oxford, Churchill Hospital
Old Rd, Headington
Oxford, United Kingdom, OX3 7LJ
T: 44-1865-857298
mark.mccarthy@drl.ox.ac.uk
ex officio
Mona Miller
Executive Director
ASHG Administrative Office
9650 Rockville Pike
Bethesda, MD 20814-3998
T: (301) 634-7300
mmiller@ashg.org